Intellia Therapeutics, Inc. NTLA
- nexiguran ziclumeran — Transthyretin Amyloidosis with Cardiomyopathy Phase 3
- nexiguran ziclumeran — Hereditary Transthyretin Amyloidosis with Polyneuropathy Phase 3
TTR (1 companies · 2 programs)
Companies with an active program directed at TTR.